UK markets closed

CymaBay Therapeutics, Inc. (0I5P.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
32.240.00 (0.00%)
At close: 05:28PM GMT
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.28
52-week change 3278.70%
S&P500 52-week change 326.89%
52-week high 332.32
52-week low 37.32
50-day moving average 325.53
200-day moving average 316.38

Share statistics

Avg vol (3-month) 32.68k
Avg vol (10-day) 32.36k
Shares outstanding 559.44M
Implied shares outstanding 6N/A
Float 896.13M
% held by insiders 10.40%
% held by institutions 1102.94%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-74,557.90%

Management effectiveness

Return on assets (ttm)-22.04%
Return on equity (ttm)-64.17%

Income statement

Revenue (ttm)31.07M
Revenue per share (ttm)0.29
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -101M
Net income avi to common (ttm)-105.37M
Diluted EPS (ttm)-1.32
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)394.26M
Total cash per share (mrq)3.44
Total debt (mrq)114.49M
Total debt/equity (mrq)39.18%
Current ratio (mrq)10.96
Book value per share (mrq)2.57

Cash flow statement

Operating cash flow (ttm)-72.53M
Levered free cash flow (ttm)-54.82M